Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck KGaA appeals for Erbitux expansion

Merck KGaA appeals for Erbitux expansion

5th September 2007

An application to include first-line therapy for the treatment of metastatic colorectal cancer (mCRC) in the uses of cancer therapy Erbitux (cetuximab) has been put to the European Medicines Agency, Merck KGaA has announced.

According to the firm, its treatment expansion appeal is supported by new data from a Crystal [Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer] study which demonstrated the efficacy of the drug on addressing first-line treatment needs in mCRC patients.

The trial – which saw a phase III study of Merck KGaA’s drug used in combination with irinotecan-based therapy, compared with the therapy alone – saw a significant increase in the average duration of progression-free survival times in patients previously untreated for their condition.

Dr Wolfgang Wein, senior executive vice-president of oncology at Merck Serono, remarks: “The positive results we have seen for Erbitux as a first-line therapy are really important.

“If approved, using Erbitux as a first-line therapy will provide a much greater hope for cure for these patients.”

Recently, Merck KGaA announced at the American Society of Clinical Oncology meeting in Chicago that a spectrum of studies has increased hopes of the effectiveness of Erbitux in patients with colorectal , head and neck cancers.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.